Outcome of Board Meeting held on 30th May, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.2 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board approved audited financial results for the quarter and year ended March 31, 2025, along with the Directors' Report, Corporate Governance Report, MD&A, and notice for the 32nd Annual General Meeting. Statutory auditors issued an unmodified (clean) opinion on the standalone financial results. The Board appointed M/s Meenu Maheshwari & Associates as Secretarial Auditor for a five-year term (subject to shareholder approval) and re-appointed Internal Auditors for FY26. Key numbers: Profit Before Tax rose to about Rs. 115.51 lakh from Rs. 98.73 lakh (~17% growth), Total Assets jumped to Rs. 1,629.58 lakh from Rs. 1,080.87 lakh, and Other Equity grew to Rs. 779.93 lakh from Rs. 693.12 lakh. However, operating cash flow sharply turned negative at Rs. -363.71 lakh versus a positive Rs. 212.08 lakh last year, driven by a steep build-up in inventories (Rs. 446.49 lakh vs Rs. 106.42 lakh) and receivables.
Clean auditor opinion and modest profit growth are positives, but the sharp swing to negative operating cash flow, near-fourfold inventory build-up, and fresh short-term borrowings of Rs. 381.35 lakh signal working-capital stress that shareholders should watch closely in coming quarters.